2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice …

FLJ Visseren, F Mach, YM Smulders… - European heart …, 2021 - academic.oup.com
Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery …

G Hindricks, T Potpara, N Dagres, E Arbelo… - European heart …, 2021 - academic.oup.com
MicroRNAs (miRNAs) are small regulatory molecules post-transcriptionally suppressing
mRNA activity. Many miRNAs in various organisms have been cloned but many unknown …

Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials

JGF Cleland, KV Bunting, MD Flather… - European heart …, 2018 - academic.oup.com
Aims Recent guidelines recommend that patients with heart failure and left ventricular
ejection fraction (LVEF) 40–49% should be managed similar to LVEF≥ 50%. We …

Atrial fibrillation in the UK: predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs

P Burdett, GYH Lip - European Heart Journal-Quality of Care …, 2022 - academic.oup.com
Aims Atrial fibrillation (AF) is the most common sustained heart arrhythmia and a major
preventable cause of stroke, heart failure, and dementia. Atrial fibrillation already accounts …

Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis

JA López-López, JAC Sterne, HHZ Thom, JPT Higgins… - bmj, 2017 - bmj.com
Objective To compare the efficacy, safety, and cost effectiveness of direct acting oral
anticoagulants (DOACs) for patients with atrial fibrillation. Design Systematic review …

Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial

D Kotecha, KV Bunting, SK Gill, S Mehta, M Stanbury… - Jama, 2020 - jamanetwork.com
Importance There is little evidence to support selection of heart rate control therapy in
patients with permanent atrial fibrillation, in particular those with coexisting heart failure …

Managing atrial fibrillation in patients with heart failure and reduced ejection fraction: a scientific statement from the American Heart Association

R Gopinathannair, LY Chen, MK Chung… - Circulation …, 2021 - Am Heart Assoc
Atrial fibrillation and heart failure with reduced ejection fraction are increasing in prevalence
worldwide. Atrial fibrillation can precipitate and can be a consequence of heart failure with …

Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes

G Filippatos, GL Bakris, B Pitt, R Agarwal… - Journal of the American …, 2021 - jacc.org
Background Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are at
risk of atrial fibrillation or flutter (AFF) due to cardiac remodeling and kidney complications …

Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European …

B Zafrir, LH Lund, C Laroche, F Ruschitzka… - European heart …, 2018 - academic.oup.com
Aim To investigate the characteristics long-term prognostic implications (up to∼ 2.2 years) of
atrial fibrillation (AF) compared to sinus rhythm (SR), between acute and chronic heart …

Epidemiology of atrial fibrillation

H Zulkifly, GYH Lip, DA Lane - International journal of clinical …, 2018 - Wiley Online Library
Background The most common type of arrhythmia in the USA and in European countries is
atrial fibrillation (AF). The prevalence of AF is increasing worldwide with advances in …